Psychoactive Drug History Questionnaire

Total Page：16

File Type：pdf, Size：1020Kb

PSYCHOACTIVE DRUG HISTORY QUESTIONNAIRE Program # _________ Client Name:__________________ Counsellor: ___________________ Date: ________________ DRUG TYPE Used in Past # of days How Long Typical Amount Clinical comments (e.g. drug name, 12 Months? used in Since Last on Each Day dosage, patterns, periods of abstinence, past 90 Drug Use? (see of Use in Yes No Refused Missing (1) NONE days codes below) the Last used only as prescribed, length of use, 1 2 8 9 90 Days* age of first use, etc.) (2) ALCOHOL: Beer/liquor/wine (3) COCAINE/CRACK: coke (4) AMPHETAMINES/OTHER STIMULANTS (5) CANNABIS: hash, weed, grass, pot, marijuana (6) BENZODIAZEPINES (7) BARBITURATES (8) HEROIN/OPIUM (9) PRESCRIPTION OPIOIDS How Long Since Last Used: 1=<24 hour 2=1-3 days 3=within last week 4=within last month 5=more than a month ago DRUG TYPE Used in Past # of days How Long Typical Amount Clinical comments (e.g. drug name, used in past Since Last on Each Day 12 Months? dosage, patterns, periods of abstinence, 90 days Drug Use? (see of Use in Yes No Refused Missing (1) NONE codes below) the Last used only as prescribed, length of use, 1 2 8 9 90 Days* age of first use, etc.) (10) OVER-THE-COUNTER CODEINE PREPARATIONS (11) HALLUCINOGENS (12) GLUE/OTHER INHALANTS (13) TOBACCO (14) OTHER PSYCHOACTIVE DRUGS How Long Since Last Used: 1=<24 hour 2=1-3 days 3=within last week 4=within last month 5=more than a month ago * See Guidelines for Describing “Amount” of Each Drug Use 90 DAY WINDOW: START DATE (dd/mm/yyyy) _______________ END DATE (Yesterday) (dd/mm/yyyy) ____________________ Addiction Research Foundation, 1997, a division of the Centre for Addiction and Mental Health. Used by permission..

Copy Link

Recommended publications

Substance Abuse: the Pharmacy Educator’S Role in Prevention and Recovery
Substance Abuse: The Pharmacy Educator’s Role in Prevention and Recovery Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease i Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease1,2 BACKGROUND OF THE CURRICULUM DEVELOPMENT PROJECT In 1988, the AACP Special Interest Group (SIG) on Pharmacy Student and Faculty Impairment (renamed Substance Abuse Education and Assistance) undertook the development of curricular guidelines for colleges/schools of pharmacy to facilitate the growth of educational opportunities for student pharmacists. These Curricular Guidelines for Pharmacy Education: Substance Abuse and Addictive Disease were published in 1991 (AJPE. 55:311-16. Winter 1991.) One of the charges of the Special Committee on Substance Abuse and Pharmacy Education was to review and revise the 1991 curricular guidelines. Overall, the didactic and experiential components in the suggested curriculum should prepare the student pharmacist to competently problem-solve issues concerning alcohol and other drug abuse and addictive diseases affecting patients, families, colleagues, themselves, and society. The guidelines provide ten educational goals, while describing four major content areas including: psychosocial aspects of alcohol and other drug use; pharmacology and toxicology of abused substances; identification, intervention, and treatment of people with addictive diseases; and legal/ethical issues. The required curriculum suggested by these guidelines addresses the 1 These guidelines were revised by the AACP Special Committee on Substance Abuse and Pharmacy Education. Members drafting the revised guidelines were Edward M. DeSimone (Creighton University), Julie C. Kissack (Harding University), David M. Scott (North Dakota State University), and Brandon J. Patterson (University of Iowa). Other Committee members were Paul W. Jungnickel, Chair (Auburn University), Lisa A.
[Show full text]
Programme & Abstracts
The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
[Show full text]
Ecstasy Or Molly, Is a Synthetic Psychoactive Drug
DRUG ENFORCEMENT ADMINISTRATION THE FACTS ABOUT MDMA Ecstasy &Molly DEA PHOTO What is it? MDMA, (3,4-methylenedioxy- methamphetamine), known as Ecstasy or Molly, is a synthetic psychoactive drug. Ecstasy is the pill form of MDMA. Molly is the slang for “molecular” that refers to the powder or crystal form of MDMA. Molly is often mixed with other drugs and substances and is not pure MDMA or safe to use. How is it used? MDMA or Ecstasy is taken orally in pill or tablet form. These pills can be in different colors with images on them. Molly is taken in a gel capsule or snorted. What does MDMA do to the body and mind? • As a stimulant drug, it increases heart rate and blood pressure. Users may experience muscle tension, involuntary teeth clenching, nausea, blurred vision, faintness, chills, or sweating • It produces feelings of increased energy, euphoria, emotional warmth, empathy, and distortions in sensory and time perception. • Feelings of sadness, anxiety, depression and memory difficulties are other effects. • It can seriously deplete serotonin levels in the brain, causing confusion and sleep problems. Did you know? • DEA has labeled MDMA as a Schedule I drug, meaning its abuse potential is high and it has no approved medical use. It is illegal in the U.S. • In high doses, MDMA can affect the body’s ability to regulate temperature, which can lead to serious health complications and possible death. • Teens are using less MDMA. Teens decreased their past year use of MDMA from 1.9% in 2010 to 1.2% of teens using 2012.
[Show full text]
Psychoactive Substances and Transpersonal States
TRANSPERSONAL PSYCHOLOGY RESEARCH REVIEW: PSYCHOACTIVE SUBSTANCES AND TRANSPERSONAL STATES David Lukoff San Francisco, California Robert Zanger Los Angeles, California Francis Lu San Francisco, California This "Research Review" covers recent trends in researching psychoactive substances and trans personal states of conscious ness during the past ten years. In keeping with the stated goals of this section of the Journal to promote research in transpersonal psychology, the focus is on the methods and trends designs which are being employed in investigations rather than during the findings on this topic. However, some recently published the books and monographs provide good summaries of the recent last findings relevant to understanding psychoactive substances ten (Cohen & Krippner, 1985b; Dobkin de Rios, 1984;Dobkin de years Rios & Winkelman, 1989b; Ratsch, 1990; Reidlinger, 1990). Because researching psychoactive substances is most broadly a cross-disciplinary venture, only a small portion of the research reviewed below was conducted by persons who consider The authors wish to acknowledge the assistance of Bruce Flath, head librarian at the California Institute of Integral Studies, San Francisco in conducting the computer bibliographic searches used in preparation of this article. The authors also wish to thank Marlene Dobkin de Rios, Stanley Krippner, Christel Lukoff, Dennis McKenna, Terence McKenna, Ralph Metzner, Donald Rothberg and Ilene Serlin for their valuable comments on earlier drafts of this article. Copyright © 1990 Transpersonal Institute The Journal of Transpersonal Psychology. 1990, Vol. 22, No.2 107 themselves transpersonal psychologists. As Vaughan (1984) has noted, "The transpersonal perspective is a meta-perspec tive, an attempt to learn from all different disciplines . emerging from the needed integration of ancient wisdom and modern science.
[Show full text]
10 Facts About MDMA
10 Facts About MDMA August 2015 1. What is MDMA? and a desire to intensify these feelings by dancing, talking and touching. MDMA, often referred to as “ecstasy” or “molly”, is short for 3,4 methylenedioxymethamphetamine, a A typical dose of 80 - 125 mg lasts three to six hours. psychoactive drug derived from safrole oil. MDMA Some people experience nausea at the outset, but produces effects that resemble both stimulants and after about 45 minutes, report feelings of relaxation psychedelics, as well as its signature effect: a feeling and clarity. MDMA also causes dilation of the pupils of connectedness. It impacts brain function primarily and, often, sensitivity to light, as well as possible jaw- releasing the neurotransmitter serotonin, and also clenching, tooth-grinding, muscle tension, faintness, temporarily inhibits its reuptake. MDMA is usually and chills or sweating. taken orally, whether in pressed pill form, powder or crystal; or sometimes snorted. After the drug wears off, the theory from preclinical studies is that brain levels of serotonin (a chemical MDMA was originally synthesized in 1912 by the drug responsible for maintaining mood balance) are company Merck.1 However, its psychoactive effects depleted, which can lead in some cases to sadness, weren’t widely discovered until 1976 when Alexander anxiety, depression and sleep problems.4 If they occur, Shulgin developed a new synthesis method, tested the these symptoms arise in the several days that follow. drug on himself, and shared it with a few friendly Generally, they abate within a week, though frequency psychotherapists.2 Because of the drug’s effects of of use and higher doses can slow or stop this increasing empathy and reducing fear, it started to be process.5 used in psychotherapy practices in the 1970s and early 80s, as well as recreationally.
[Show full text]
Commonly Used Drugs
Commonly Used Drugs Many drugs can alter a person’s thinking and judgment, and can lead to health risks, including addiction, drugged driving, infectious disease, and adverse effects on pregnancy. Information on commonly used drugs with the potential for misuse or addiction can be found here. For information about treatment options for substance use disorders, see NIDA’s Treatment pages. For drug use trends, see our Trends and Statistics page. For the most up-to-date slang terms, please see Slang Terms and Code Words: A Reference for Law Enforcement Personnel (DEA, PDF, 1MB). The following drugs are included in this resource: ➢ Alcohol ➢ Methamphetamine ➢ Ayahuasca ➢ Over-the-Counter Medicines--Dextromethorphan ➢ Central Nervous System Depressants (DXM) ➢ Cocaine ➢ Over-the-Counter Medicines--Loperamide ➢ DMT ➢ PCP ➢ GHB ➢ Prescription Opioids ➢ Hallucinogens ➢ Prescription Stimulants ➢ Heroin ➢ Psilocybin ➢ Inhalants ➢ Rohypnol® (Flunitrazepam) ➢ Ketamine ➢ Salvia ➢ Khat ➢ Steroids (Anabolic) ➢ Kratom ➢ Synthetic Cannabinoids ➢ LSD ➢ Synthetic Cathinones ("Bath Salts") ➢ Marijuana (Cannabis) ➢ Tobacco/Nicotine ➢ MDMA (Ecstasy/Molly) ➢ Mescaline (Peyote) **Drugs are classified into five distinct categories or schedules “depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential.” More information and the most up-to-date scheduling information can be found on the Drug Enforcement Administration’s website. June 2020 Alcohol People drink to socialize, celebrate, and relax. Alcohol often has a strong effect on people—and throughout history, people have struggled to understand and manage alcohol’s power. Why does alcohol cause people to act and feel differently? How much is too much? Why do some people become addicted while others do not? The National Institute on Alcohol Abuse and Alcoholism is researching the answers to these and many other questions about alcohol.
[Show full text]
Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: Achildpsychiatrist’S Perspective
Neurotherapeutics DOI 10.1007/s13311-017-0531-1 REVIEW Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: AChildPsychiatrist’s Perspective Ben Sessa1 # The Author(s) 2017. This article is an open access publication Abstract Since the late 1980s the psychoactive drug 3,4- pharmacotherapies and psychotherapies for treating complex methylenedioxymethamphetamine (MDMA) has had a well- post-traumatic stress disorder arising from child abuse. known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as Key Words MDMA . PTSD . Psychotherapy . Trauma . a therapeutic agent and that in recent years an increasing Psychedelics . addictions amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmaco- logical properties that translate well to its proposed agent to Introduction: From Child Abuse and Mental assist trauma-focused psychotherapy. Psychological trauma— Disorder to Addictions especially that which arises early in life from child abuse— and 3,4-Methylenedioxymethamphetamine underpins many chronic adult mental disorders, including ad- dictions. Several studies of recent years have investigated the I am a child and adolescent psychiatrist, who also works with potential role of MDMA-assisted psychotherapy as a treat- adults with addictions. My adult patients in their 20s, 30s, and ment for post-traumatic stress disorder, with ongoing plans beyond with unremitting depression, anxiety, post-traumatic to see MDMA therapy licensed and approved within the next stress disorder (PTSD), and substance abuse are sadly the 5 years. Issues of safety and controversy frequently surround same type of patients that I also care for as abused children.
[Show full text]
Hallucinogenic Mushrooms: a Guide
Hallucinogenic Mushrooms: A Guide Presented by the Hamre Center for Health and Wellness Table of Contents Introduction Harm Reduction What are Hallucinogenic Mushrooms? What are the U.S. and MN Laws Surrounding Mushrooms? What Kinds of Hallucinogenic Mushrooms are There? How are Hallucinogenic Mushrooms Ingested? How Do Hallucinogenic Mushrooms Affect the Brain? What are Some Short-Term Effects of Use? What are Some Long-Term Effects of Use? How Do Hallucinogenic Mushrooms Interact with Alcohol? What are Some Harm-Reduction Strategies for Use? Are Hallucinogenic Mushrooms Addictive? What are Some Substance Abuse Help Resources? Introduction Welcome to the Hamre Center’s hallucinogenic mushrooms guide! Thank you for wanting to learn more about “magic mushrooms” and how they can affect you. This guide is designed to be a science-based resource to help inform people about hallucinogenic mushrooms. We use a harm-reduction model, which we’ll talk about more in the next slide. If you have any concerns regarding your own personal health and mushrooms, we strongly recommend that you reach out to your health care provider. No matter the legal status of hallucinogenic mushrooms in your state or country, health care providers are confidential resources. Your health is their primary concern. Harm Reduction ● The harm reduction model used in this curriculum is about neither encouraging or discouraging use; at its core, harm reduction simply aims to minimize the negative consequences of behaviors. ● Please read through the Hamre Center’s statement on use and harm reduction below: “The Hamre Center knows pleasure drives drug use, not the avoidance of harm.
[Show full text]
Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3Rd Floor Seacole Building 2
ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor Seacole Building 2. Marsham Street London SW1P 4DF 020 7035 0454 Email: [email protected] Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 18th October 2012 Dear Home Secretary, In March 2012 the ACMD advised that methoxetamine be subject to a temporary class drug order. Methoxetamine was marketed as a legal alternative to ketamine until a temporary class drug order was implemented in April 2012. As is now required, the ACMD has followed its initial assessment with a consideration of methoxetamine in the context of the Misuse of Drugs Act 1971; I enclose the report with this letter. The chemical structure of methoxetamine bears a close resemblance to that of both ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well- documented and serious adverse effects following both acute and chronic usage. Users report that the effects of methoxetamine are similar to those of ketamine, however, some users report that the effects are of longer duration.The harmful effects reported include severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant hallucinations. The first analytically confirmed series reported by Guy‟s and St Thomas‟ NHS Foundation Trust, London in 2011, was of three individuals who presented having self-reported use of methoxetamine. All three presented with a ketamine-like dissociative state, but also had significant stimulant effects with agitation and cardiovascular effects including tachycardia and hypertension. Toxicological screening of serum samples confirmed methoxetamine use in two of the cases.
[Show full text]
Psychoactive Substance Profile (All Drugs)
PSYCHOACTIVE SUBSTANCE PROFILE: Codeine What is the street/slang name(s)? Lean, sizzurp, purple drank, purp, syrup, and dirty sprite. Is this substance considered a depressant, stimulant, hallucinogenic? Depressant and an Opiate. How is this substance typically taken? It is a cough syrup, so it is taken by mouth. What are the desired effects of this substance (be thorough)? Motor skills impairment, lethargy, pain relief, drowsiness, mild euphoria, and hallucinations. How prevalent is the use of this substance in the United States? Very popular in the hip hop and rap communities. It originated in Houston. In 2004, the University of Texas found that 8.3% of college students in Texas had taken codeine syrup to get high. From a poll of 2,000 young adults, 6.5% of them had tried lean. Can one develop a tolerance to this substance? Yes. What side effects may result from continued use of this substance? Seizures and heart attacks. Is there an abstinence syndrome (withdrawal) related to the use of this substance? If so, describe some of the symptoms. Muscle aches, insomnia, anxiety, runny nose, sweating, stomach cramps, nausea and vomiting. PSYCHOACTIVE SUBSTANCE PROFILE: Adderall What is the street/slang name(s)? Addy Is this substance considered a depressant, stimulant, hallucinogenic? Stimulant How is this substance typically taken? Orally What are the desired effects of this substance (be thorough)? Adderall is used to treat ADHD and narcolepsy. It helps one focus on one thing at a time, keeps one alert and awake. How prevalent is the use of this substance in the United States? Consumption rate has gone up about %70-%80 since the 1990’s.
[Show full text]
Psychedelic Agents
PSYCHEDELIC AGENTS: CHANGES INDUCED IN SUBJECTIVE EXPERIENCE AND BRAIN ACTIVITY Bachelor Degree Project in Cognitive Neuroscience Basic level 22.5 ECTS Spring term 2019 Louise Andersson Supervisor: Katja Valli Examiner: Joel Parthemore Abstract This thesis combines phenomenological and neuroscientific research to elucidate the effects of psychedelic agents on the human brain, mind and psychological well-being. Psychoactive plants have been used for thousands of years for ceremonial and ritual purposes. Psychedelics are psychoactive substances that affect cognitive processes and alter perception, thoughts, and mood. Illegalization of psychedelics in the 1960s rendered them impossible to study empirically but in the last couple of decades, relaxed legal restrictions regarding research purposes, renewed interest in the effects of psychedelic drugs and new brain imaging techniques have started to reveal the possibilities of these mind-altering substances. Psychedelics mainly affect the serotonin receptor 5-HT2A which in turn affects the functioning of largescale cortical areas by changing cerebral blood flow, alpha oscillations and functional connectivity. These cortical changes not only induce immediate alterations in perception and cognition but have been shown to have positive effects in therapeutic interventions for depression, anxiety, and addiction, and also positively affect well-being in general. Although the pharmacology and neurobiology of psychedelics are still poorly understood, the potential benefits justify empirical research
[Show full text]
Review of the Psychoactive Substances Act 2016
Review of the Psychoactive Substances Act 2016 November 2018 Review of the Psychoactive Substances Act 2016 Presented to Parliament pursuant to Section 58 of the Psychoactive Substances Act 2016 November 2018 © Crown copyright 2018 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open- government-licence/version/3 Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at www.gov.uk/government/publications Any enquiries regarding this publication should be sent to us at [email protected] ISBN 978-1-5286-0863-3 CCS1118903070 11/18 Printed on paper containing 75% recycled fibre content minimum Printed in the UK by the APS Group on behalf of the Controller of Her Majesty’s Stationery Office Review of the Psychoactive Substances Act 2016 Contents Acknowledgements 3 Executive Summary 4 Introduction 8 Chapter 1: Legislation 13 Chapter 2: Enforcement 16 Chapter 3: Sales and availability 29 Chapter 4: Prevalence 39 Chapter 5: Health and social harms 52 Chapter 6: Conclusions 69 1 Review of the Psychoactive Substances Act 2016 2 Review of the Psychoactive Substances Act 2016 Acknowledgements Thanks are due to officials from a wide range of government departments, agencies and devolved administrations who contributed to this report, including those from: • Crown Office and Procurator Fiscal Service
[Show full text]